The Peptide NewsroomPeptide research, industry and supply-chain headlines

Telehealth Firms Market Off-Label GLP-1s for Addiction, But No Drug Is Approved Yet

By The Peptide Newsroom Desk · Date: 0views 0comments
Topic card: fda

A STAT News report says a handful of telehealth platforms specializing in addiction treatment have begun marketing off-label GLP-1 prescriptions for alcohol use disorder and other addictions. The marketing started in the last year, well ahead of any regulatory decision on the question.

GLP-1s are the drug class behind the popular diabetes and obesity medications, and addiction medicine is one of several possible next acts for them. The telehealth companies are prescribing both branded and compounded versions, according to the report.

The trials that are actually running

The formal research is moving, just not as fast as the storefronts. Eli Lilly is investigating a new drug called brenipatide and testing it in alcohol use disorder, STAT reports.

A new company, Baseline Therapeutics, is studying a GLP-1 receptor agonist in alcohol, cocaine, and methamphetamine use disorders. Altimmune is testing one called pemvidutide for alcohol.

Why the stakes are high here

Addiction medicine specialists quoted in the report are hopeful the Food and Drug Administration may soon approve a new medication for alcohol use disorder. It would be the first in two decades.

That gap explains a lot about why this lane is moving the way it is. A field that has waited twenty years for a new option is a field where demand runs well ahead of the evidence, and direct-to-consumer telehealth is built to meet demand quickly.

The off-label gap

Off-label prescribing is legal and routine, and clinicians do it across medicine every day. Marketing an unapproved use directly to consumers is a different exercise, and it is the part of this story worth watching.

The compounded piece adds another layer. Compounded GLP-1s sit outside the approval and manufacturing path that the branded versions went through, and stacking that on top of an unapproved indication means two separate questions are being answered by the platform rather than by a regulator.

Bottom line

The science on GLP-1s and substance use disorder is in trials right now, with at least three companies running programs and no approval in hand. What is already on the market is a commercial offer built on that expectation.

Whether the trials land is the question that settles this, and it has not been settled. Until then, the distance between what is being studied and what is being sold is the whole story.

Source: STAT News. Read the original.

Filed under: fda, glp-1, safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Retatrutide Sourcing Checklist Sets a 99% Purity Bar, But It Is Sponsored Content

A sponsored checklist in Pharmaceutical Technology argues that labs buying retatrutide should demand lot-specific, third-party certificates of analysis rather than trust a vendor's purity claim. The analytical standards are sound, but the article resolves into a single named supplier.

NAD+ Is Everywhere in Longevity Marketing, But the Human Evidence Stays Thin

NAD+ is a coenzyme involved in energy metabolism and DNA repair, and it has become one of longevity marketing's biggest names. A review of two recent sources finds the human evidence for supplementing it remains mixed, unpublished, or self-reported.

Omada Says Coaching Program Doubled Weight Loss in GLP-1 Users, But Trial Was Small

Omada Health will present peer-reviewed research in Boston reporting that members of its GLP-1 coaching program lost 6.0% of body weight at 12 weeks versus 3.3% for usual care. The study followed 245 adults, was company-produced, and ran for only three months.